The four-gene signature (CLN6, GMPR, AP1S2, ITGA6) and their validated roles in proliferation/migration (e.g., CLN6 knockdown suppressing tumor growth) provide novel therapeutic targets. The gene discussed is AP1S2; the disease is neoplasm.